Trevi Therapeutics, Inc. TRVI Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s share based compensation arrangement by share based payment award fair value assumptions risk free interest rate maximum.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s share based compensation arrangement by share based payment award fair value assumptions risk free interest rate maximum?
- Trevi Therapeutics, Inc. (TRVI) reported share based compensation arrangement by share based payment award fair value assumptions risk free interest rate maximum of 4.4% in Q4 2025.
- What does share based compensation arrangement by share based payment award fair value assumptions risk free interest rate maximum mean?
- Represents the maximum risk-free interest rate utilized in the Black-Scholes or similar option-pricing models to value employee stock-based compensation awards. This rate is typically based on the yield of U.S. Treasury securities with a maturity matching the expected term of the awards. It serves as a key input in determining the fair value of equity grants issued to employees.